HRTX
Heron Therapeutics Inc
Price:  
1.60 
USD
Volume:  
1,754,436.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HRTX WACC - Weighted Average Cost of Capital

The WACC of Heron Therapeutics Inc (HRTX) is 7.6%.

The Cost of Equity of Heron Therapeutics Inc (HRTX) is 9.50%.
The Cost of Debt of Heron Therapeutics Inc (HRTX) is 6.15%.

Range Selected
Cost of equity 7.70% - 11.30% 9.50%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.30% - 7.00% 6.15%
WACC 6.3% - 8.9% 7.6%
WACC

HRTX WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.84 1.15
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.70% 11.30%
Tax rate 26.20% 27.00%
Debt/Equity ratio 0.61 0.61
Cost of debt 5.30% 7.00%
After-tax WACC 6.3% 8.9%
Selected WACC 7.6%